Luredean Hamilton-Brandon
Family Medicine · Hickory, NCNPI 1629006994
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $898 and has fallen 85.6% since, to $129 in 2024.
Across 117 payments — averaging $29.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$593
- AstraZeneca$534
- Biohaven Pharmaceuticals, Inc.$424
- AbbVie$367
- Valeritas, Inc.$238
- GSK$138
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,39199%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $593 |
| AstraZeneca | 6 | $534 |
| Biohaven Pharmaceuticals, Inc. | 4 | $424 |
| AbbVie(2 entities) | 22 | $367 |
| Valeritas, Inc. | 3 | $238 |
| GSK | 9 | $138 |
| Novo Nordisk | 6 | $126 |
| Pfizer | 7 | $122 |
| Amgen | 2 | $104 |
| Mannkind Corporation | 1 | $100 |
| Exact Sciences | 2 | $100 |
| Abbott | 1 | $85 |
| Supernus Pharmaceuticals, Inc. | 4 | $71 |
| Dexcom, Inc. | 2 | $49 |
| Novartis | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 3 | $37 |
| Gilead | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Merck | 2 | $25 |
| Bayer | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,409 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Novolog FlexpenInsulin Aspart | 11 | $837 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Hickory
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.